Roth Says Use of New Promacta May Provide 'Meaningful' Royalties, EPS Growth to Ligand

An analyst at Roth Capital, Joseph Pantginis, earlier noted Ligand (NASDAQ: LGND ) may see EPS growth of up to $0.35 over the next few years, as a result of “meaningful” royalty income from Promacta(R) . The product is used to treat persons with severe aplastic anemia (SAA). Pantginis maintains